Publications by authors named "Brian Grabowski"

Claim this Profile
A
Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.
Brian Grabowski, Ronald D Lee

Clin Drug Investig· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
Brian A Grabowski, Reza Khosravan, Laurent Vernillet, Darcy J Mulford

J Clin Pharmacol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
Brian Grabowski, Reza Khosravan, Jing-Tao Wu, Laurent Vernillet, Christopher Lademacher

Br J Clin Pharmacol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.
Reza Khosravan, Brian Grabowski, Jing-Tao Wu, Nancy Joseph-Ridge, Laurent Vernillet

Br J Clin Pharmacol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Reza Khosravan, Brian A Grabowski, Jing-Tao Wu, Nancy Joseph-Ridge, Laurent Vernillet

Clin Pharmacokinet· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar).
Robert A Carr, Amy K André, Ping Chen, Brian A Grabowski, Min S Chang

Nephron Clin Pract· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Reza Khosravan, Brian A Grabowski, Michael D Mayer, Jing-Tao Wu, Nancy Joseph-Ridge

J Clin Pharmacol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
Gondi N Kumar, Venkata K Jayanti, Marianne K Johnson, John Uchic, Samuel Thomas, Brian A Grabowski

Pharm Res· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis